Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 11, 2008, Pages 853-856

  Osone, Shinya ^a,b   Hosoi, Hajime ^a   Tsuchiya, Kunihiko ^a   Misawa, Akiko ^a,c   Iehara, Tomoko ^a   Sugimoto, Tohru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO CITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Irinotecan; Neuroblastoma; Palliative chemotherapy; Performance status; Quality of life

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; ETOPOSIDE; HOMOVANILLIC ACID; IFOSFAMIDE; IODINE 123; IRINOTECAN; ISOTRETINOIN; LOPERAMIDE; NEURON SPECIFIC ENOLASE; PIRARUBICIN; VANILMANDELIC ACID; CAMPTOTHECIN; DRUG DERIVATIVE;

ADVANCED CANCER; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FANCONI ANEMIA; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; NEPHROTOXICITY; NEUROBLASTOMA; PALLIATIVE THERAPY; PARALYTIC ILEUS; PNEUMATOSIS INTESTINALIS; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SKULL IRRADIATION; TREATMENT OUTCOME; TUMOR BIOPSY; XERODERMA; INFANT; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; NEUROBLASTOMA; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 58149143289     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318180bb71     Document Type: Article

References (15)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006:933-970.
2. Bomgaars L, Berg SL, Blaney SM. The development of camptothe-cin analogs in childhood cancers. Oncologists. 2001;6:506-516.
3. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999;17:1815-1824.
4. Kushner BH, Kramer K, Modak S, et al. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer.2005;103:858- 862.
5. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol. 2007;25:4622-4627.
6. Suita S, Tajiri T, Kaneko M, et al. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy. J Pediatr Surg. 2007;42:489-493.
7. Lansky SB, List MA, Lansky LL, et al. The measurement of performance status in childhood cancer patients. Cancer.1987;60: 1651-1656.
8. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054-1060.
9. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol. 2006; 24:563-570.
10. Kushner BH, Kramer K, Cheung N-KV. Chronic neuroblastoma - indolent stage 4 disease in children. Cancer.2002;95:1366-1375.
11. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer.2007;48:132-139.
12. Santos A, Calvet L, Terrier-Lacombe M-J, et al. In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations. Cancer Res. 2004;64: 3223-3229.
13. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst. 2001;93:618-629.
14. Collado R, Badia L, García S, et al. Chromosome 11 abnormality in myelodysplastic syndromes. Cancer Genet Cytogenet. 1999;114: 58-61.
15. Rubin CM, Arthur DC, Woods WG, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood. 1991;78:2982-2988.